Aurora-A kinase inhibitor scaffolds and binding modes

Brown, 2005, COX-2: a molecular target for colorectal cancer prevention, J. Clin. Oncol., 4, 2840, 10.1200/JCO.2005.09.051

Sardon, 2009, Development and biological evaluation of a novel Aurora A kinase inhibitor, ChemBioChem, 10, 464, 10.1002/cbic.200800600

Pollard, 2009, Discovery and development of Aurora kinase inhibitors as anticancer agents, J. Med. Chem., 52, 2629, 10.1021/jm8012129

Kitzen, 2010, Aurora kinase inhibitors, Crit. Rev. Oncol. Hematol., 73, 99, 10.1016/j.critrevonc.2009.03.009

Malumbres, 2007, Cell cycle kinases in cancer, Curr. Opin. Genet. Dev., 17, 60, 10.1016/j.gde.2006.12.008

Nigg, 2001, Mitotic kinases as regulators of cell division and its checkpoints, Nat. Rev. Mol. Cell Biol., 2, 21, 10.1038/35048096

Mountzios, 2008, Aurora kinases as targets for cancer therapy, Cancer Treat. Rev., 34, 175, 10.1016/j.ctrv.2007.09.005

Giet, 2005, Aurora kinases, aneuploidy and cancer, a coincidence or a real link?, Trends Cell Biol., 15, 241, 10.1016/j.tcb.2005.03.004

Wang, 2010, Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora kinase inhibitors, J. Med. Chem., 53, 4367, 10.1021/jm901913s

Mahadevan, 2007, Aurora kinase targeted therapeutics in oncology: past, present and future, Expert Opin. Drug Discov., 2, 1011, 10.1517/17460441.2.7.1011

Yang, 2005, Mitotic requirement for Aurora A kinase is bypassed in the absence of Aurora B kinase, FEBS Lett., 579, 3385, 10.1016/j.febslet.2005.04.080

Aliagas-Martin, 2009, A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B, J. Med. Chem., 52, 3300, 10.1021/jm9000314

Lok, 2010, Aurora kinase inhibitors as anti-cancer therapy, Anticancer Drugs, 21, 339, 10.1097/CAD.0b013e3283350dd1

Li, 2004, Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C, J. Biol. Chem., 279, 47201, 10.1074/jbc.M403029200

Sasai, 2004, Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells, Cell Motil. Cytoskeleton, 59, 249, 10.1002/cm.20039

Giet, 1999, Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases, J. Cell Sci., 112, 3591, 10.1242/jcs.112.21.3591

Crane, 2004, Requirements for the destruction of human Aurora-A, J. Cell Sci., 117, 5975, 10.1242/jcs.01418

Walter, 2000, The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation, Oncogene, 19, 4906, 10.1038/sj.onc.1203847

Bayliss, 2003, Structural basis of Aurora-A activation by TPX2 at the mitotic spindle, Mol. Cell, 12, 851, 10.1016/S1097-2765(03)00392-7

Littlepage, 2002, Identification of phosphorylated residues that affect the activity of the mitotic kinase aurora-A, Proc. Natl. Acad. Sci. U. S. A., 99, 15440, 10.1073/pnas.202606599

Talele, 2008, Molecular docking/dynamics studies of Aurora A kinase inhibitors, J. Mol. Graph. Model., 26, 1213, 10.1016/j.jmgm.2007.11.003

Fancelli, 2005, Potent and selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition, J. Med. Chem., 48, 3080, 10.1021/jm049076m

Heron, 2006, SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors, Bioorg. Med. Chem. Lett., 16, 1320, 10.1016/j.bmcl.2005.11.053

Fancelli, D. et al. (2007) [Nerviano Medical Sciences] Preparation of 1H-thieno[2,3-c]pyrazoles as kinase, particularly Aurora kinases and IGF-1R inhibitors for treating cancer. PIXXD2 WO 2007009898 A1 20070125

Barberis, C. et al. (2006) [Aventis Pharma] Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases. PIXXD2 WO 2006092510 A1 20060908

Carry, J.C. et al. (2006) [Aventis Pharma] Substituted 1H-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases for treating cancer. PIXXD2 WO 2006056697 A1 20060601

Mauger, J. et al. (2007) [Aventis Pharma] Preparation of 1,4-dihydropyridine-fused heterocycles as inhibitors of Aurora kinases. EPXXDW EP 1746097 A1 20070124

Moriarty, 2006, The synthesis and SAR of 2-amino-pyrrolo [2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors, Bioorg. Med. Chem. Lett., 16, 5778, 10.1016/j.bmcl.2006.08.080

Fischer, P.M. et al. (2006)[Cyclacel Ltd.] Preparation of 4-(1H-indol-3-yl)-pyrimidin-2-ylamine derivatives as protein kinase inhibitors and their use in therapy. PIXXD2 WO 2006075152 A1 20060720

Tabart, M. et al. (2006) [Aventis Pharma] Preparation of substituted pyrrolopyridines as kinase inhibitors, and their compositions and use for treatment of cancer. FRXXBL FR 2884821 A1 20061027

Georges, G. et al. (2006) [F. Hoffmann-La Roche] Preparation of pyrazolylbenzimidazole derivatives as Aurora A kinase inhibitors for treatment of cancer. PIXXD2 WO 2006032519 A1 20060330

Bavetsias, V. et al. (2007) [Chroma Therapeutics Ltd.] Preparation of imidazopyridines as enzyme inhibitors, especially Aurora kinase inhibitors, for treating cell proliferative diseases. PIXXD2 WO 2007072017 A2 20070628

Lew, W. et al. (2006) [Sunesis Pharmaceuticals] Thienopyrimidines useful as Aurora kinase inhibitors and their preparation, pharmaceutical compositions, and their use for treatment of Aurora kinase-mediated diseases. USXXCO US 2006035908 A1 20060216

Davidson, A.H. et al. (2006) [Chroma Therapeutics Ltd.] Preparation of quinoline and quinazoline amino acid derivatives as inhibitors of kinase enzymatic activity. PIXXD2 WO 2006117552 A1 20061109

Tomozane, H. et al. (2005) [Mitsubishi Pharma Corporation] Preparation of aminopyrimidine derivatives as aurora 2 kinase inhibitors for treatment of cancer. PIXXD2 WO 2005113550 A1 20051201

Adams, J.L. et al. (2007) [Smithkline Beecham Corporation] Pyrimidinyl-pyrazole inhibitors of Aurora kinases and their preparation, pharmaceutical compositions and use in the treatment of cell proliferative diseases. PIXXD2 WO 2007024843 A2 20070301

Jones, S. et al. (2007) [Cyclacel Ltd.] Preparation of pyrimidinyl substituted pyrrolopyrazinones as protein kinase inhibitors useful in treatment of diseases. PIXXD2 WO 2007042784 A2 20070419

Krueger, E.B. et al. (2008) [Genentech, Inc.] Preparation of pyrimidines as Aurora kinase inhibitors. PIXXD2 WO 2008079719 A1 20080703

Howard, 2009, Fragment-based discovery of the pyrazol-4-yl urea (AT9283). A multitargeted kinase inhibitor with potent Aurora kinase activity, J. Med. Chem., 52, 379, 10.1021/jm800984v

Zhong, 2009, 2-Aminobenzimidazoles as potent Aurora kinase inhibitors, Bioorg. Med. Chem. Lett., 19, 5158, 10.1016/j.bmcl.2009.07.016

Cheung, 2009, Aurora kinase inhibitors in preclinical and testing, Expert Opin. Investig. Drugs, 18, 379, 10.1517/13543780902806392

Fancelli, 2006, 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile, J. Med. Chem., 49, 7247, 10.1021/jm060897w

Tari, 2007, Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors, Bioorg. Med. Chem. Lett., 17, 688, 10.1016/j.bmcl.2006.10.086

Zhao, 2008, Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2, Protein Sci., 17, 1791, 10.1110/ps.036590.108

Manfredi, 2007, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase, Proc. Natl. Acad. Sci. U. S. A., 104, 4106, 10.1073/pnas.0608798104

Gadea, 2005, Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts, Mol. Biol. Cell, 16, 1305, 10.1091/mbc.E04-10-0891

Ikezoe, 2007, A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia, Mol. Cancer Ther., 6, 1851, 10.1158/1535-7163.MCT-07-0067

Harrington, 2004, VX-680, a potent and selective small molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo, Nat. Med., 10, 262, 10.1038/nm1003

Montembault, 2005, Aurora kinases: therapeutic potential, Drug Fut., 30, 1, 10.1358/dof.2005.030.01.875304

Jones, S.F. et al. (2007) Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase. J. Clin. Oncol., 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 3577. (http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34708)